Lombard Odier Asset Management Europe Ltd Invests $2.62 Million in Boston Scientific Corporation $BSX

Lombard Odier Asset Management Europe Ltd acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 61,349 shares of the medical equipment provider’s stock, valued at approximately $2,618,000.

Other institutional investors also recently modified their holdings of the company. Kingsview Wealth Management LLC bought a new position in Boston Scientific during the second quarter worth $230,000. Beacon Pointe Advisors LLC acquired a new stake in Boston Scientific in the second quarter worth $679,000. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Boston Scientific in the second quarter valued at $419,000. Rakuten Investment Management Inc. bought a new stake in Boston Scientific in the second quarter valued at $10,570,000. Finally, Glenview Trust Co acquired a new position in shares of Boston Scientific during the second quarter valued at about $10,845,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Boston Scientific Price Performance

BSX stock opened at $46.82 on Friday. The business has a 50-day simple moving average of $46.56 and a two-hundred day simple moving average of $56.65. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts expect that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BSX. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Canaccord Genuity Group decreased their target price on Boston Scientific from $70.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. BTIG Research cut their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. Finally, Wells Fargo & Company reduced their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.